Clinical Study
Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
Table 2
Comparison of VAS scores in older (≥80 years old) and younger (<60 years old) BTX-A therapeutic groups.
| ||||||||||||||||||||||||||||||||||||||||
: comparison of VAS scores between before treatment and after treatment; : comparison of VAS scores between older group and younger group. |